# Episode 407: Pharmacology 101: CAR T-Cell Immunotherapy

Page: https://stenobird.com/podcast/the-ons-podcast-1126448/episode-407-pharmacology-101-car-t-cell-immunotherapy
Text version: https://stenobird.com/podcast/the-ons-podcast-1126448/episode-407-pharmacology-101-car-t-cell-immunotherapy.md
Podcast: [The ONS Podcast](https://stenobird.com/podcast/the-ons-podcast-1126448)
Published: 2026-03-20T07:00:00+00:00
Episode link: https://onsvoice.libsyn.com/episode-407-pharmacology-101-car-t-cell-immunotherapy
Audio file: https://traffic.libsyn.com/secure/onsvoice/Final_-_CAR_T-Cell_Therapy_mixdown.mp3?dest-id=557038
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-ons-podcast-1126448/episodes/episode-407-pharmacology-101-car-t-cell-immunotherapy
Duration seconds: 2911

## Resource

"You want to try to act quickly and be able to know what the pathways are for appropriate escalating when a patient is having symptoms that are reflective of cytokine release syndrome (CRS) or neurotoxicity. These toxicities are very manageable and treatable when recognized early. To summarize, choosing the right patient, knowing the toxicity profile for each product, and acting early is really what helps to prevent severe outcomes with chimeric antigen receptor (CAR) T-cell therapy," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS ® , manager of oncology nursing practice at ONS, during a conversation about CAR T-cell immunotherapy. Music Credit: " Fireflies and Stardust " by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by March 20, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to CAR T-Cell immunotherapy in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD . ONS Podcast ™ episodes: Pharmacology 101 series Episode 267: Side-Effect Management for CAR T-Cell Therapy for Hematologic Malignancies Episode 261: CAR T-Cell Therapy for Hematologic Malignancies Requires Education and Navigation Episode 176: Oncologic Emer…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-ons-podcast-1126448/episodes/episode-407-pharmacology-101-car-t-cell-immunotherapy/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-ons-podcast-1126448/episode-407-pharmacology-101-car-t-cell-immunotherapy.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.